Tempest to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Summary

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company, announced that CEO Stephen R. Brady will present at the H.C. Wainwright 24th Annual Global Investment Conference. The presentation will be available on-demand starting September 12, 2022, at 7:00 a.m. ET on the Tempest investor website. The company is focused on developing innovative therapeutics, including its lead candidates, TPST-1120 and TPST-1495, which target various tumor mechanisms. More details can be found on the company's website.

News Market Reaction – TPST

+11.40%

+11.40% Session move

In the trading session that priced this news, TPST gained 11.40%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class¹ therapeutics that combine both targeted and immune-mediated mechanisms, today announced that Stephen R. Brady, chief executive officer of Tempest, will present at the H.C. Wainwright 24^th Annual Global Investment Conference. The company presentation will be available for on-demand viewing Monday, September 12, 2022, at 7:00 a.m. ET on the investor section of the Tempest website at https://ir.tempesttx.com.

About Tempest Therapeutics

Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s two novel clinical programs are TPST-1120 and TPST-1495, antagonists of PPARα and EP2/EP4, respectively. Both programs are advancing through clinical trials designed to study the agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally available inhibitor of TREX-1, a target that controls activation of the cGAS/STING pathway. Tempest is headquartered in South San Francisco. More information about Tempest can be found on the company’s website at www.tempesttx.com.

Investor Contacts:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com

Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com

---

¹ If approved by the FDA

FAQ

When will Tempest Therapeutics present at the H.C. Wainwright 24th Annual Global Investment Conference?

Tempest Therapeutics will present at the conference on September 12, 2022, at 7:00 a.m. ET.

Where can I watch the Tempest Therapeutics conference presentation?

The presentation will be available for on-demand viewing on the Tempest investor section of their website.

What are the lead candidates being developed by Tempest Therapeutics?

Tempest Therapeutics is developing TPST-1120 and TPST-1495, targeting tumor mechanisms.

What is the focus of Tempest Therapeutics?

Tempest Therapeutics focuses on developing first-in-class therapeutics for oncology using targeted and immune-mediated mechanisms.

What is the stock symbol for Tempest Therapeutics?

The stock symbol for Tempest Therapeutics is TPST.